ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Pulmonary Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,921Medicare Part D Prescriptions Filled, Including Refills

Rank: 2 out of 167

$822K Total Retail Price of All Prescriptions

Rank: 11 out of 167

539 Patients Receiving at Least One Drug in Part D
73%Patients 65 Years and Older
51% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in North Carolina
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 539 patients filled at least one prescription for a schedule two drug, compared to an average of 0%.

Schedule Three
Controlled Substances

5% of this provider’s 539 patients filled at least one prescription for a schedule three drug, compared to an average of 1%.

Risky Drugs to Seniors

2% of this provider’s 7,237 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

34% of this provider’s prescriptions were for brand-name drugs, compared to an average of 57%.

Prescription Price

$83 was the average price of a prescription from this provider, compared to $178 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 9.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in North Carolina
FUROSEMIDE 549 436 1 12
SPIRIVA 360 239 2 1
LEVOTHYROXINE SODIUM 346 277 3 18
OMEPRAZOLE 338 253 4 6
PREDNISONE 321 216 5 3
ADVAIR DISKUS 320 181 6 2
LISINOPRIL 305 231 7 16
METFORMIN HCL 238 177 8 25
TRAMADOL HCL 237 173 9 36
SYMBICORT 226 147 10 5
POTASSIUM CHLORIDE 187 143 11 23
LOVASTATIN 183 156 12 97
PROAIR HFA 174 68 13 4
AZITHROMYCIN 173 126 14 7
ATENOLOL 171 106 15 40
METOPROLOL TARTRATE 169 141 16 19
SINGULAIR 150 103 17 9
ATORVASTATIN CALCIUM 146 124 18 27
AMOX TR-POTASSIUM CLAVULANATE 135 98 19 62
VENTOLIN HFA 131 73 20 10
NEXIUM 127 48 21 32
PANTOPRAZOLE SODIUM 127 99 21 29
ADVAIR HFA 123 69 23 46
AMLODIPINE BESYLATE 122 116 24 15
KLOR-CON M20 116 104 25 55
SIMVASTATIN 112 66 26 13
CYCLOBENZAPRINE HCL 109 72 R 27 59
CIPROFLOXACIN HCL 108 77 28 38
AMITRIPTYLINE HCL 106 63 R 29 73
SERTRALINE HCL 103 81 30 41
COMBIVENT 102 86 31 11
ZOLPIDEM TARTRATE 97 62 32 21
WARFARIN SODIUM 89 66 33 28
MONTELUKAST SODIUM 86 56 34 17
GLIPIZIDE 82 76 35 77
SPIRONOLACTONE 78 55 36 54
SYNTHROID 71 65 37 52
TRIAMTERENE-HCTZ 66 60 38 156
DIOVAN 66 61 38 51
CARVEDILOL 65 45 40 76
TRICOR 60 43 41 116
ALENDRONATE SODIUM 52 41 42 42
TAMSULOSIN HCL 52 36 42 49
HYDROCODONE-ACETAMINOPHEN 51 41 S3 44 14
FLUOXETINE HCL 50 43 45 111
FLUCONAZOLE 50 39 45 90
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 19, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.